Dr Hannah Bayes

  • Honorary Clinical Senior Lecturer (School of Infection & Immunity)

email: Hannah.Bayes@glasgow.ac.uk

Department of Respiratory Medicine, Glasgow Royal Infirmary, Castle Street, G4 0SF

Import to contacts

Publications

List by: Type | Date

Jump to: 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010
Number of items: 23.

2023

Berry, C. et al. (2023) Mental health symptoms and illness trajectory following COVID-19 hospitalization: A cohort study. Heart and Mind, 7(4), pp. 235-245. (doi: 10.4103/hm.HM-D-23-00037)

Sykes, R. et al. (2023) Adjudicated myocarditis and multisystem illness trajectory in healthcare workers post-COVID-19. Open Heart, 10(1), e002192. (doi: 10.1136/openhrt-2022-002192) (PMID:36822817) (PMCID:PMC9950584)

2022

Mangion, K. et al. (2022) Multi-system investigation of COVID-19 illness. British Cardiovascular Society Annual Conference, ‘100 years of Cardiology’, Manchester, UK, 06-08 June 2022. A122.1-A122. (doi: 10.1136/heartjnl-2022-BCS.157)

Morrow, A. J. et al. (2022) A multisystem, cardio-renal investigation of post-COVID-19 illness. Nature Medicine, 28(6), pp. 1303-1313. (doi: 10.1038/s41591-022-01837-9) (PMID:35606551) (PMCID:PMC9205780)

Morrow, A. et al. (2022) Prevention and early treatment of the long-term physical effects of COVID-19 in adults: design of a randomised controlled trial of resistance exercise—CISCO-21. Trials, 23, 660. (doi: 10.1186/s13063-022-06632-y) (PMID:35971155) (PMCID:PMC9376905)

2021

Abani, O. et al. (2021) Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. Lancet, 397(10289), pp. 2049-2059. (doi: 10.1016/S0140-6736(21)00897-7) (PMID:34000257) (PMCID:PMC8121538)

Abani, O. et al. (2021) Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet, 397(10285), pp. 1637-1645. (doi: 10.1016/S0140-6736(21)00676-0) (PMID:33933206) (PMCID:PMC8084355)

Abaleke, E. et al. (2021) Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet, 397(10274), pp. 605-612. (doi: 10.1016/S0140-6736(21)00149-5) (PMID:33545096) (PMCID:PMC7884931)

2020

Mangion, K. et al. (2020) The Chief Scientist Office cardiovascular and pulmonary imaging in SARS Coronavirus disease-19 (CISCO-19) study. Cardiovascular Research, 116(14), pp. 2185-2196. (doi: 10.1093/cvr/cvaa209) (PMID:32702087) (PMCID:PMC7454350)

2019

Irvine, S., Bunk, B., Bayes, H. K., Spröer, C., Connolly, J. P.R., Six, A., Evans, T. J. , Roe, A. J. , Overmann, J. and Walker, D. (2019) Genomic and transcriptomic characterization of Pseudomonas aeruginosa small colony variants derived from a chronic infection model. Microbial Genomics, 5(4), (doi: 10.1099/mgen.0.000262) (PMID:30920365) (PMCID:PMC6521587)

2018

Ritchie, N. D., Ritchie, R., Bayes, H. K., Mitchell, T. J. and Evans, T. J. (2018) IL-17 can be protective or deleterious in murine pneumococcal pneumonia. PLoS Pathogens, 14(5), e1007099. (doi: 10.1371/journal.ppat.1007099) (PMID:29813133) (PMCID:PMC5993294)

2017

Bayes, H. K., McInnes, I. B. and Chalmers, G. W. (2017) Castleman disease and lymphocytic interstitial pneumonia: a complex diagnostic and management challenge. Rheumatology, 56(4), pp. 665-668. (doi: 10.1093/rheumatology/kew420) (PMID:28013210)

2016

Bayes, H. K., Ritchie, N. D. and Evans, T. J. (2016) Interleukin-17 is required for control of chronic lung infection caused by Pseudomonas aeruginosa. Infection and Immunity, 84(12), pp. 3507-3516. (doi: 10.1128/IAI.00717-16) (PMID:27698020) (PMCID:PMC5116727)

Bayes, H.K., Ritchie, N., Irvine, S. and Evans, T.J. (2016) A murine model of early Pseudomonas aeruginosa lung disease with transition to chronic infection. Scientific Reports, 6, 35838. (doi: 10.1038/srep35838) (PMID:27804985) (PMCID:PMC5090221)

Bayes, H. K., Ritchie, N. E., Ward, C., Corris, P. A., Brodlie, M. and Evans, T. (2016) IL-22 exacerbates weight loss in a murine model of chronic pulmonary Pseudomonas aeruginosa infection. Journal of Cystic Fibrosis, 16(6), pp. 759-768. (doi: 10.1016/j.jcf.2016.06.008) (PMID:27375092) (PMCID:PMC5154339)

Bayes, H. K. and Cowan, D. C. (2016) Biomarkers and asthma management. Current Opinion in Allergy and Clinical Immunology, 16(3), pp. 210-217. (doi: 10.1097/aci.0000000000000263) (PMID:27057795)

2015

Jabir, M. et al. (2015) Mitochondrial damage contributes to Pseudomonas aeruginosa activation of the inflammasome and is downregulated by autophagy. Autophagy, 11(1), pp. 166-182. (doi: 10.4161/15548627.2014.981915) (PMID:25700738) (PMCID:PMC4502769)

2014

Jabir, M. S. et al. (2014) Caspase-1 cleavage of the TLR adaptor TRIF inhibits autophagy and β-interferon production during pseudomonas aeruginosa infection. Cell Host and Microbe, 15(2), pp. 214-227. (doi: 10.1016/j.chom.2014.01.010) (PMID:24528867)

Bayes, H. K., Bicknell, S., MacGregor, G. and Evans, T. J. (2014) T helper cell subsets specific for pseudomonas aeruginosa in healthy individuals and patients with cystic fibrosis. PLoS ONE, 9(2), e90263. (doi: 10.1371/journal.pone.0090263) (PMID:24587305) (PMCID:PMC3937364)

2013

Bayes, H.K., Church, A.C. and Fisher, A.J. (2013) Review of the British Thoracic Society Winter meeting 2012, 5 to 7 December, London, UK. Thorax, 68(3), pp. 277-282. (doi: 10.1136/thoraxjnl-2012-203165)

2012

Bayes, H., Church, A. and Fisher, A.J. (2012) Review of the British Thoracic Society Winter Meeting 2011, 7-9 December, London, UK. Thorax, 67(3), pp. 258-262. (doi: 10.1136/thoraxjnl-2012-201597)

2011

Bayes, H. K. (2011) Serological data improves estimates of infection during 2009 H1N1 pandemic. Thorax, 66(1), p. 60. (doi: 10.1136/thx.2010.145565)

2010

Bayes, H. K., Oyeniran, O., Shepherd, M. and Walters, M. (2010) Clinical Audit: Management of Acute Severe Asthma in West Glasgow. Scottish Medical Journal, 55(1), pp. 6-9. (doi: 10.1258/rsmsmj.55.1.6)

This list was generated on Sat Mar 2 06:15:12 2024 GMT.
Number of items: 23.

Articles

Berry, C. et al. (2023) Mental health symptoms and illness trajectory following COVID-19 hospitalization: A cohort study. Heart and Mind, 7(4), pp. 235-245. (doi: 10.4103/hm.HM-D-23-00037)

Sykes, R. et al. (2023) Adjudicated myocarditis and multisystem illness trajectory in healthcare workers post-COVID-19. Open Heart, 10(1), e002192. (doi: 10.1136/openhrt-2022-002192) (PMID:36822817) (PMCID:PMC9950584)

Morrow, A. J. et al. (2022) A multisystem, cardio-renal investigation of post-COVID-19 illness. Nature Medicine, 28(6), pp. 1303-1313. (doi: 10.1038/s41591-022-01837-9) (PMID:35606551) (PMCID:PMC9205780)

Morrow, A. et al. (2022) Prevention and early treatment of the long-term physical effects of COVID-19 in adults: design of a randomised controlled trial of resistance exercise—CISCO-21. Trials, 23, 660. (doi: 10.1186/s13063-022-06632-y) (PMID:35971155) (PMCID:PMC9376905)

Abani, O. et al. (2021) Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. Lancet, 397(10289), pp. 2049-2059. (doi: 10.1016/S0140-6736(21)00897-7) (PMID:34000257) (PMCID:PMC8121538)

Abani, O. et al. (2021) Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet, 397(10285), pp. 1637-1645. (doi: 10.1016/S0140-6736(21)00676-0) (PMID:33933206) (PMCID:PMC8084355)

Abaleke, E. et al. (2021) Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet, 397(10274), pp. 605-612. (doi: 10.1016/S0140-6736(21)00149-5) (PMID:33545096) (PMCID:PMC7884931)

Mangion, K. et al. (2020) The Chief Scientist Office cardiovascular and pulmonary imaging in SARS Coronavirus disease-19 (CISCO-19) study. Cardiovascular Research, 116(14), pp. 2185-2196. (doi: 10.1093/cvr/cvaa209) (PMID:32702087) (PMCID:PMC7454350)

Irvine, S., Bunk, B., Bayes, H. K., Spröer, C., Connolly, J. P.R., Six, A., Evans, T. J. , Roe, A. J. , Overmann, J. and Walker, D. (2019) Genomic and transcriptomic characterization of Pseudomonas aeruginosa small colony variants derived from a chronic infection model. Microbial Genomics, 5(4), (doi: 10.1099/mgen.0.000262) (PMID:30920365) (PMCID:PMC6521587)

Ritchie, N. D., Ritchie, R., Bayes, H. K., Mitchell, T. J. and Evans, T. J. (2018) IL-17 can be protective or deleterious in murine pneumococcal pneumonia. PLoS Pathogens, 14(5), e1007099. (doi: 10.1371/journal.ppat.1007099) (PMID:29813133) (PMCID:PMC5993294)

Bayes, H. K., McInnes, I. B. and Chalmers, G. W. (2017) Castleman disease and lymphocytic interstitial pneumonia: a complex diagnostic and management challenge. Rheumatology, 56(4), pp. 665-668. (doi: 10.1093/rheumatology/kew420) (PMID:28013210)

Bayes, H. K., Ritchie, N. D. and Evans, T. J. (2016) Interleukin-17 is required for control of chronic lung infection caused by Pseudomonas aeruginosa. Infection and Immunity, 84(12), pp. 3507-3516. (doi: 10.1128/IAI.00717-16) (PMID:27698020) (PMCID:PMC5116727)

Bayes, H.K., Ritchie, N., Irvine, S. and Evans, T.J. (2016) A murine model of early Pseudomonas aeruginosa lung disease with transition to chronic infection. Scientific Reports, 6, 35838. (doi: 10.1038/srep35838) (PMID:27804985) (PMCID:PMC5090221)

Bayes, H. K., Ritchie, N. E., Ward, C., Corris, P. A., Brodlie, M. and Evans, T. (2016) IL-22 exacerbates weight loss in a murine model of chronic pulmonary Pseudomonas aeruginosa infection. Journal of Cystic Fibrosis, 16(6), pp. 759-768. (doi: 10.1016/j.jcf.2016.06.008) (PMID:27375092) (PMCID:PMC5154339)

Bayes, H. K. and Cowan, D. C. (2016) Biomarkers and asthma management. Current Opinion in Allergy and Clinical Immunology, 16(3), pp. 210-217. (doi: 10.1097/aci.0000000000000263) (PMID:27057795)

Jabir, M. et al. (2015) Mitochondrial damage contributes to Pseudomonas aeruginosa activation of the inflammasome and is downregulated by autophagy. Autophagy, 11(1), pp. 166-182. (doi: 10.4161/15548627.2014.981915) (PMID:25700738) (PMCID:PMC4502769)

Jabir, M. S. et al. (2014) Caspase-1 cleavage of the TLR adaptor TRIF inhibits autophagy and β-interferon production during pseudomonas aeruginosa infection. Cell Host and Microbe, 15(2), pp. 214-227. (doi: 10.1016/j.chom.2014.01.010) (PMID:24528867)

Bayes, H. K., Bicknell, S., MacGregor, G. and Evans, T. J. (2014) T helper cell subsets specific for pseudomonas aeruginosa in healthy individuals and patients with cystic fibrosis. PLoS ONE, 9(2), e90263. (doi: 10.1371/journal.pone.0090263) (PMID:24587305) (PMCID:PMC3937364)

Bayes, H.K., Church, A.C. and Fisher, A.J. (2013) Review of the British Thoracic Society Winter meeting 2012, 5 to 7 December, London, UK. Thorax, 68(3), pp. 277-282. (doi: 10.1136/thoraxjnl-2012-203165)

Bayes, H., Church, A. and Fisher, A.J. (2012) Review of the British Thoracic Society Winter Meeting 2011, 7-9 December, London, UK. Thorax, 67(3), pp. 258-262. (doi: 10.1136/thoraxjnl-2012-201597)

Bayes, H. K. (2011) Serological data improves estimates of infection during 2009 H1N1 pandemic. Thorax, 66(1), p. 60. (doi: 10.1136/thx.2010.145565)

Bayes, H. K., Oyeniran, O., Shepherd, M. and Walters, M. (2010) Clinical Audit: Management of Acute Severe Asthma in West Glasgow. Scottish Medical Journal, 55(1), pp. 6-9. (doi: 10.1258/rsmsmj.55.1.6)

Conference or Workshop Item

Mangion, K. et al. (2022) Multi-system investigation of COVID-19 illness. British Cardiovascular Society Annual Conference, ‘100 years of Cardiology’, Manchester, UK, 06-08 June 2022. A122.1-A122. (doi: 10.1136/heartjnl-2022-BCS.157)

This list was generated on Sat Mar 2 06:15:12 2024 GMT.